Mesenchymal Stromal Cells Perspective: New Potential Therapeutic for the Treatment of Neurological Diseases

Mukai, Takeo; Sei, Kenshi; Nagamura‐Inoue, Tokiko

doi:10.3390/pharmaceutics13081159

Cited by 8 publications

(6 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, their application has been tested in diverse pre-clinical animal models with encouraging results. In this section, we will concentrate on the findings of the beneficial actions of ASC, while the effect of MSC from other sources, e.g., of bone marrow or umbilical origin, are described elsewhere [ 11 , 35 , 60 ]. There are three ways to administrate ASC in vivo: (i) transplantation of cells, (ii) injection of ASC-CM, or (iii) injection of ASC-EV.…”

Section: Application Of Asc In Vivomentioning

confidence: 99%

Switching Roles: Beneficial Effects of Adipose Tissue-Derived Mesenchymal Stem Cells on Microglia and Their Implication in Neurodegenerative Diseases

et al. 2022

View full text Add to dashboard Cite

Neurological disorders, including neurodegenerative diseases, are often characterized by neuroinflammation, which is largely driven by microglia, the resident immune cells of the central nervous system (CNS). Under these conditions, microglia are able to secrete neurotoxic substances, provoking neuronal cell death. However, microglia in the healthy brain carry out CNS-supporting functions. This is due to the ability of microglia to acquire different phenotypes that can play a neuroprotective role under physiological conditions or a pro-inflammatory, damaging one during disease. Therefore, therapeutic strategies focus on the downregulation of these neuroinflammatory processes and try to re-activate the neuroprotective features of microglia. Mesenchymal stem cells (MSC) of different origins have been shown to exert such effects, due to their immunomodulatory properties. In recent years, MSC derived from adipose tissue have been made the center of attention because of their easy availability and extraction methods. These cells induce a neuroprotective phenotype in microglia and downregulate neuroinflammation, resulting in an improvement of clinical symptoms in a variety of animal models for neurological pathologies, e.g., Alzheimer’s disease, traumatic brain injury and ischemic stroke. In this review, we will discuss the application of adipose tissue-derived MSC and their conditioned medium, including extracellular vesicles, in neurological disorders, their beneficial effect on microglia and the signaling pathways involved.

show abstract

Section: Application Of Asc In Vivomentioning

confidence: 99%

Switching Roles: Beneficial Effects of Adipose Tissue-Derived Mesenchymal Stem Cells on Microglia and Their Implication in Neurodegenerative Diseases

et al. 2022

View full text Add to dashboard Cite

show abstract

“…On the other hand, Clark et al have utilized the experimental autoimmune encephalomyelitis (EAE) murine model of MS to show that human placental MSC (hP-MSC)-derived EVs promote remyelination (Clark et al, 2019). They demonstrated that, as opposed to the control group, animals treated with hP-MSCs and hP-MSC-EVs displayed increased "differentiation of endogenous oligodendrocyte precursor cells into mature myelinating oligodendrocytes" (Mukai et al, 2021), resulting in an improved motor function in those groups. Furthermore, mice in these groups exhibited less DNA damage to oligodendrocytes.…”

Section: Multiple Sclerosismentioning

confidence: 99%

Mesenchymal stem cell therapy for neurological disorders: The light or the dark side of the force?

Isakovic

Šerer

Barišić

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Neurological disorders are recognized as major causes of death and disability worldwide. Because of this, they represent one of the largest public health challenges. With awareness of the massive burden associated with these disorders, came the recognition that treatment options were disproportionately scarce and, oftentimes, ineffective. To address these problems, modern research is increasingly looking into novel, more effective methods to treat neurological patients; one of which is cell-based therapies. In this review, we present a critical analysis of the features, challenges, and prospects of one of the stem cell types that can be employed to treat numerous neurological disorders—mesenchymal stem cells (MSCs). Despite the fact that several studies have already established the safety of MSC-based treatment approaches, there are still some reservations within the field regarding their immunocompatibility, heterogeneity, stemness stability, and a range of adverse effects—one of which is their tumor-promoting ability. We additionally examine MSCs’ mechanisms of action with respect to in vitro and in vivo research as well as detail the findings of past and ongoing clinical trials for Parkinson’s and Alzheimer’s disease, ischemic stroke, glioblastoma multiforme, and multiple sclerosis. Finally, this review discusses prospects for MSC-based therapeutics in the form of biomaterials, as well as the use of electromagnetic fields to enhance MSCs’ proliferation and differentiation into neuronal cells.

show abstract

“…Because MSCs can generate new neurons or other neural supporting cells, they are also an attractive target to develop treatment for neurodegenerative or neuroinflammatory disorders [ 29 , 30 ]. MSC-based therapy has been proven to be effective in ischemic stroke, neurodegenerative diseases, brain and spinal cord injuries [ 31 ], although in many cases, the exact mechanism of their therapeutic action remains to be elucidated.…”

Section: Mesenchymal Stem Cells (Mscs) and Their Therapeutic Potential For Brain Diseasesmentioning

confidence: 99%

Application of Mesenchymal Stem Cells in Targeted Delivery to the Brain: Potential and Challenges of the Extracellular Vesicle-Based Approach for Brain Tumor Treatment

Duy

Kurniawati

Hsieh

et al. 2021

IJMS

View full text Add to dashboard Cite

Treating brain tumors presents enormous challenges, and there are still poor prognoses in both adults and children. Application of novel targets and potential drugs is hindered by the function of the blood-brain barrier, which significantly restricts therapeutic access to the tumor. Mesenchymal stem cells (MSCs) can cross biological barriers, migrate to sites of injuries to exert many healing effects, and be engineered to incorporate different types of cargo, making them an ideal vehicle to transport anti-tumor agents to the central nervous system. Extracellular vesicles (EVs) produced by MSCs (MSC-EVs) have valuable innate properties from parent cells, and are being exploited as cell-free treatments for many neurological diseases. Compared to using MSCs, targeted delivery via MSC-EVs has a better pharmacokinetic profile, yet avoids many critical issues of cell-based systems. As the field of MSC therapeutic applications is quickly expanding, this article aims to give an overall picture for one direction of EV-based targeting of brain tumors, with updates on available techniques, outcomes of experimental models, and critical challenges of this concept.

show abstract

Mesenchymal Stromal Cells Perspective: New Potential Therapeutic for the Treatment of Neurological Diseases

Cited by 8 publications

References 98 publications

Switching Roles: Beneficial Effects of Adipose Tissue-Derived Mesenchymal Stem Cells on Microglia and Their Implication in Neurodegenerative Diseases

Switching Roles: Beneficial Effects of Adipose Tissue-Derived Mesenchymal Stem Cells on Microglia and Their Implication in Neurodegenerative Diseases

Mesenchymal stem cell therapy for neurological disorders: The light or the dark side of the force?

Application of Mesenchymal Stem Cells in Targeted Delivery to the Brain: Potential and Challenges of the Extracellular Vesicle-Based Approach for Brain Tumor Treatment

Contact Info

Product

Resources

About